• Alper MG, Zimmerman LE & Piana FG (1983): Orbital manifestations of Erdheim–Chester disease. Trans Am Ophthalmol Soc 81: 6485.
  • Bullock JD, Bartley GB, Campbell RJ, Yanes B, Connelly PJ & Funkhouser JW (1986): Necrobiotic xanthogranuloma with paraproteinemia. Case report and a pathogenetic theory. Ophthalmology 93: 12331236.
  • Char DH, LeBoit PE, Ljung BM & Wara W (1987): Radiation therapy for ocular necrobiotic xanthogranuloma. Arch Ophthalmol 105: 174175.
  • Cruz AA, de Alencar VM, Falcao MF, Elias J Jr & Chahud F (2006): Association between Erdheim–Chester disease, Hashimoto thyroiditis, and familial thrombocytopenia. Ophthal Plast Reconstr Surg 22: 6062.
  • Elner VM, Mintz R, Demirci H & Hassan AS (2006): Local corticosteroid treatment of eyelid and orbital xanthogranuloma. Ophthal Plast Reconstr Surg 22: 3640.
  • Finan MC & Winkelmann RK (1986): Necrobiotic xanthogranuloma with paraproteinemia. A review of 22 cases. Medicine (Baltimore) 65: 376388.
  • Goede JS, Misselwitz B, Taverna C, Schanz U, Dispenzieri A, Hummel Y, Trueb RM & Fehr J (2007): Necrobiotic xanthogranuloma successfully treated with autologous stem cell transplantation. Ann Hematol 86: 303306.
  • Hayden A, Wilson DJ & Rosenbaum JT (2007): Management of orbital xanthogranuloma with methotrexate. Br J Ophthalmol 91: 434436.
  • Ho VH, Chevez-Barrios P, Jorgensen JL, Silkiss RZ & Esmaeli B (2007): Receptor expression in orbital inflammatory syndromes and implications for targeted therapy. Tissue Antigens 70: 105109.
  • Jakobiec FA, Mills MD, Hidayat AA, Dallow RL, Townsend DJ, Brinker EA & Charles NC (1993): Periocular xanthogranulomas associated with severe adult-onset asthma. Trans Am Ophthalmol Soc 91: 99125.
  • Karcioglu ZA, Sharara N, Boles TL & Nasr AM (2003): Orbital xanthogranuloma: clinical and morphologic features in eight patients. Ophthal Plast Reconstr Surg 19: 372381.
  • Mehregan DA & Winkelmann RK (1992): Necrobiotic xanthogranuloma. Arch Dermatol 128: 94100.
  • Meyer S, Szeimies RM, Landthaler M & Hohenleutner S (2005): Cyclophosphamide-dexamethasone pulsed therapy for treatment of recalcitrant necrobiotic xanthogranuloma with paraproteinemia and ocular involvement. Br J Dermatol 153: 443445.
  • Myra C, Sloper L, Tighe PJ et al. (2004): Treatment of Erdheim–Chester disease with cladribine: a rational approach. Br J Ophthalmol 88: 844847.
  • Oumeish OY, Oumeish I, Tarawneh M, Salman T & Sharaiha A (2006): Necrobiotic xanthogranuloma associated with paraproteinemia and non-Hodgkin’s lymphoma developing into chronic lymphocytic leukemia: the first case reported in the literature and review of the literature. Int J Dermatol 45: 306310.
  • Patel AA, Swerlick RA & McCall CO (2006): Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol 55: 369389.
  • Robertson DM & Winkelmann RK (1984): Ophthalmic features of necrobiotic xanthogranuloma with paraproteinemia. Am J Ophthalmol 97: 173183.
  • Schaudig U & Al-Samir K (2004): Upper and lower eyelid reconstruction for severe disfiguring necrobiotic xanthogranuloma. Orbit 23: 6576.
  • Sivak-Callcott JA, Rootman J, Rasmussen SL et al. (2006): Adult xanthogranulomatous disease of the orbit and ocular adnexa: new immunohistochemical findings and clinical review. Br J Ophthalmol 90: 602608.
  • Torabian SZ, Fazel N & Knuttle R (2006): Necrobiotic xanthogranuloma treated with chlorambucil. Dermatol Online J 12: 11.
  • Ugurlu S, Bartley GB & Gibson LE (2000): Necrobiotic xanthogranuloma: long-term outcome of ocular and systemic involvement. Am J Ophthalmol 129: 651657.
  • Vieira V, Del Pozo J, Martinez W, Veiga-Barreiro JA & Fonseca E (2005): Necrobiotic xanthogranuloma associated with lymphoplasmacytic lymphoma. Palliative treatment with carbon dioxide laser. Eur J Dermatol 15: 182185.
  • Zelger B, Eisendle K, Mensing C & Zelger B (2007): Detection of spirochetal micro-organisms by focus-floating microscopy in necrobiotic xanthogranuloma. J Am Acad Dermatol 57: 10261030.
  • Ziemer M, Wedding U, Sander CS & Elsner P (2005): Necrobiotic xanthogranuloma – rapid progression under treatment with melphalan. Eur J Dermatol 15: 363365.